Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 03
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
BioCryst Pharmaceuticals Inc
BCRX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$8.17
0.05
0.62%
Dern. MÀJ: Oct 2, 5:46 PM
$8.15
0.03
0.37%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
BioCryst Pharma Financials
BioCryst Pharma (BCRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.
Benzinga Newsdesk
PRO
BioCryst Pharma Q2 EPS $0.30, Sales $218.250M Beat $182.514M Estimate
Benzinga Newsdesk
PRO
BioCryst Shifts Pipeline Strategy, Reaffirms Sales Outlook Of $635.00M-$660.00M Vs 670.47M
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today announced that, as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline, it will
Benzinga Newsdesk
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.
Avi Kapoor
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $650.217M Est
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $650.217 million estimate.
Benzinga Newsdesk
